Dr. Mads Daugaard is the Co-founder, President and Chief Scientific Officer at biotech company, Rakovina Therapeutics. Founded in 2020, Rakovina is striving to revolutionize cancer treatment and extend the lives of cancer patients. Not yet in human clinical trials, they are developing medicines that selectively target and kill cancer cells using leading-edge science that we’ll discuss with Mads in this episode. The therapeutics company has 3 research programs, Kt-2000, 3000 and 4000, all of which are in the preclinical stage of drug development. Rakovina is currently being traded on the TSX Venture Exchange under the symbol RKV.

On April 8th in New Orleans, Mads is attending the American Association for Cancer Research or AACR annual meeting, which is the largest cancer research conference.  Following that he is sharing an abstract highlighting Rakovina’s KT-3000 series at AACR’s special conference on Sarcoma cancer in Montreal. The episode highlights why it is so important for Rakovina and other preclinical biotech companies to attend conferences like these. 

To learn more about Rakovina's presentation at the AARC conference, you can view their press release here.
To continue your dive into biotech investing, check out this blog series featuring Rakovina: Myths and Risks in Biotech Investing

Rakovina Therapeutics
Website 
LinkedIn 
Twitter

Red Thread Ventures 
Website
LinkedIn 
Youtube

Ver todos los episodios